Jump to content

Lorvotuzumab mertansine

From Wikipedia, the free encyclopedia
Lorvotuzumab mertansine
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetCD56
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine.)[citation needed]

Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer).[1][2]

It has been granted Orphan drug status for Merkel cell carcinoma.[3]

It has reported encouraging Phase II results for small-cell lung cancer.[4]

References

[edit]
  1. ^ Dimond PF (9 March 2010). "Antibody-Drug Conjugates Stage a Comeback". Genetic Engineering & Biotechnology News.
  2. ^ ImmunoGen reports encouraging clinical data of IMGN901. News-medical.net. Retrieved on 2010-11-20.
  3. ^ "ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC". News-Medical.net. 8 March 2010.
  4. ^ "ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer". 2009.[permanent dead link]